The launch of MGI's co-funding program, along with its upcoming webinar, will help advance research in the genomic sequencing space
TORONTO, May 16, 2022 — MGI, a company committed to being a world-leading life science innovator, launched its co-funding program called 'The Great Canadian Sequencing Challenge' on April 8 in Canada, to help more researchers access high-quality, cost-effective sequencing with DNA Nanoball technology.
MGI is at the forefront of innovation in genomic sequencing, providing them with the unique opportunity to launch others forward in sequencing innovation. The Great Canadian Sequencing Challenge will offer three prize options. The first prize will receive a free loan of the DNBSEQ sequencer*, the second prize will receive up to 50 percent off their purchase of MGI products in next sequencing project and the third prize will receive up to 40 percent off their purchase of MGI products in project.
Special awards will also be given in a few select categories. One $20,000 grant will be given to a project making contributions to women's health, and MGI will give 15 percent off to every facility that applies, providing accessibility to innovate in the genomics space.
To further lead the way in the genomic space, MGI is hosting a webinar in partnership with the University of British Columbia, called 'Decoding Ligan-Receptor Circuits Involved in Progressive Cardiac Fibrosis' on May 19th. Presenters Dr. Zachary Laksman, MD., Dr. Leili Rohani, PhD and Dr. Derek Toms, PhD. from the University of British Columbia will deliver a comprehensive overview of research in the study of cardiac arrhythmias using MGI’s genomic sequencing*.
During this webinar, the University of British Columbia team will discuss their research tools and methods, as well as the results of their research and how it has led to advancements in the study of cardiac arrhythmias. Participants in this webinar, consisting of clinical researchers and cardiologists, will have the opportunity to ask questions and learn more about MGI's sequencing technologies* and how they can benefit various research initiatives.
Both the webinar and the co-funding program serve a similar purpose: for genomic sequencing to see its full potential and to promote advanced life science tools for future health care. These programs will educate, make resources more accessible, and explore news horizons in genomic sequencing.
The Great Canadian Sequencing Challenge is open to applications from genomics researchers in Canada. Applications will be received up until May 31, 2022, and winners will be announced on June 30, 2022. Decoding Ligan-Receptor Circuits Involved in Progressive Cardiac Fibrosis will take place on May 19, 2022, at 8:00 AM Pacific Standard Time and 11:00 AM Eastern Standard Time.
MGI Tech Co., Ltd. (MGI), an affiliate of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2020, MGI has a footprint that spans across more than 70 countries and regions, serves over 1,000 international users and employs more than 1,700 professionals globally, around 33% of which are R&D personnel. For more information, please visit the MGI website or connect on Twitter, LinkedIn or YouTube.
*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, and Austria.